In­di­a's gener­ic drug mak­er Glen­mark draws up a US-based brand­ed drugs unit

Is­rael’s Te­va — the world’s largest gener­ic drug­mak­er — isn’t the on­ly one look­ing to cap­i­tal­ize on brand­ed drugs. In­di­an gener­ic drug man­u­fac­tur­er Glen­mark is mak­ing in­no­v­a­tive drugs a pri­or­i­ty too, by spin­ning off its ros­ter of new chem­i­cal and bi­o­log­i­cal en­ti­ties in­to a US-based unit.

The bulk of Glen­mark’s busi­ness is gener­ics, but it has start­ed adding some spe­cial­ty treat­ments to the mix – in its last re­port­ed quar­ter, Glen­mark made a for­ay in­to the der­ma­tol­ogy drugs busi­ness in the Unit­ed States by ac­quir­ing the rights to sev­en brand­ed prod­ucts from Ex­eltis USA. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER